Table 1. Clinicopathological characteristics by NKG2D ligand.
| Characteristic | Number (n=91) | ULBP1 | ULBP2/5/6 | ULBP3 | ULBP4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| low | high | p | low | high | p | low | high | p | low | high | p | |||
| Age | 67.8 (37-83) | 66.6±8.6 | 69.1±8.1 | 0.165 | 68.8±7.2 | 66.7±9.4 | 0.241 | 67.7±8.2 | 68.1±9.4 | 0.872 | 71.3±7.1 | 66.2±8.5 | 0.007 * | |
| Gender | Male | 59 (65%) | 27 | 32 | 0.127 | 26 | 33 | 0.093 | 48 | 11 | 0.297 | 20 | 39 | 0.380 |
| Female | 32 (35%) | 20 | 12 | 20 | 12 | 23 | 9 | 8 | 24 | |||||
| Smokinga | Never | 33 (37%) | 20 | 13 | 0.170 | 20 | 13 | 0.126 | 25 | 8 | 0.726 | 8 | 25 | 0.364 |
| Current or former | 57 (63%) | 26 | 31 | 25 | 32 | 45 | 12 | 19 | 38 | |||||
| CEA (ng/ml) | 11.6±35.4 | 6.4±11.3 | 0.355 | 5.6±10.4 | 12.6±36.3 | 0.208 | 9.9±30.1 | 4.2±4.0 | 0.404 | 5.0±3.3 | 10.8±31.9 | 0.337 | ||
| SUVmax | 8.2±6.1 | 6.5±4.3 | 0.126 | 7.7±5.7 | 7.1±4.9 | 0.604 | 7.1±5.5 | 6.6±4.8 | 0.708 | 6.8±5.8 | 7.6±5.1 | 0.469 | ||
| Tumor size (mm) | 30.1±13.0 | 30.7±13.5 | 0.818 | 28.8±11.1 | 32.0±15.0 | 0.240 | 31.2±13.8 | 27.5±10.7 | 0.261 | 31.6±13.9 | 29.9±12.9 | 0.562 | ||
| Histology | Adenocarcinoma | 71 (78%) | 41 | 30 | 0.028 * | 40 | 31 | 0.037 * | 54 | 17 | 0.394 | 18 | 53 | 0.035 * |
| Squamous cell carcinoma | 20 (22%) | 6 | 14 | 6 | 14 | 17 | 3 | 10 | 10 | |||||
| Histlogic grade | G1 | 38 (42%) | 20 | 18 | 0.611 | 24 | 14 | 0.126 | 30 | 8 | 0.264 | 9 | 29 | 0.327 |
| G2 | 29 (32%) | 13 | 16 | 12 | 17 | 20 | 9 | 9 | 20 | |||||
| G3 | 24 (26%) | 14 | 10 | 10 | 14 | 21 | 3 | 10 | 14 | |||||
| Pleural invasion | Negative | 59 (65%) | 30 | 29 | 0.836 | 33 | 26 | 0.163 | 46 | 13 | 0.986 | 19 | 40 | 0.687 |
| Positive | 32 (35%) | 17 | 15 | 13 | 19 | 25 | 7 | 9 | 23 | |||||
| Lymphatic invasion | Negative | 66 (73%) | 36 | 30 | 0.369 | 34 | 32 | 0.765 | 51 | 15 | 0.779 | 20 | 46 | 0.876 |
| Positive | 25 (27%) | 11 | 14 | 12 | 13 | 20 | 5 | 8 | 17 | |||||
| Vascular invasion | Negative | 54 (59%) | 27 | 27 | 0.704 | 30 | 24 | 0.249 | 43 | 11 | 0.655 | 13 | 41 | 0.095 |
| Positive | 37 (41%) | 20 | 17 | 16 | 21 | 28 | 9 | 15 | 22 | |||||
| Lymphnode metastasis | N0 | 72 (79%) | 38 | 34 | 0.675 | 38 | 34 | 0.408 | 58 | 14 | 0.256 | 23 | 49 | 0.636 |
| N1-2 | 19 (21%) | 9 | 10 | 8 | 11 | 13 | 6 | 5 | 14 | |||||
| Pathological stage | IA | 35 (38%) | 20 | 15 | 0.407 | 21 | 14 | 0.154 | 26 | 9 | 0.496 | 11 | 24 | 0.914 |
| IB-IIIA | 56 (62%) | 27 | 29 | 25 | 31 | 45 | 11 | 17 | 39 | |||||
a:
Data not available for one patient.
CEA: carcinoembryonic antigen, SUVmax: maximum standardized uptake value.
*
p<0.05